van Ojik, Heidi H <br/><br/>
CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.  [electronic resource] 

 -  Cancer research  Sep 2003 
 - 5595-600 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0008-5472 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--pharmacology<br/>Animals<br/>Antibodies, Bispecific--immunology<br/>Antibodies, Monoclonal--immunology<br/>Antibody-Dependent Cell Cytotoxicity--drug effects<br/>Cell Division--drug effects<br/>CpG Islands--immunology<br/>Drug Synergism<br/>Female<br/>Granulocytes--drug effects<br/>Humans<br/>Immunization, Passive--methods<br/>Immunoglobulin G--immunology<br/>Killer Cells, Natural--drug effects<br/>Lymphoma--immunology<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Inbred C3H<br/>Mice, Inbred C57BL<br/>Oligonucleotides--immunology<br/>Receptor, ErbB-2--immunology<br/>Receptors, IgG--biosynthesis<br/>Up-Regulation